PL2504005T3 - Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby - Google Patents

Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Info

Publication number: PL2504005T3
Authority: PL; Poland
Prior art keywords: diphenylprop; derivatives; treatment; liver disorders; disorders
Prior art date: 2009-11-26

Application number

PL10787363T

Other languages

English (en)

Inventor

Raphaël Darteil

Rémy Hanf

Dean Hum

Ingrid Dufour

Original Assignee

Genfit

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-26

Filing date

2010-11-26

Publication date

2014-03-31

2010-11-26 Application filed by Genfit filed Critical Genfit

2014-03-31 Publication of PL2504005T3 publication Critical patent/PL2504005T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Child & Adolescent Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL10787363T 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby PL2504005T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09306146		2009-11-26
EP10787363.0A EP2504005B1 (en)	2009-11-26	2010-11-26	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
PCT/EP2010/068346 WO2011064350A1 (en)	2009-11-26	2010-11-26	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (1)

Publication Number	Publication Date
PL2504005T3 true PL2504005T3 (pl)	2014-03-31

Family

ID=43587223

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10787363T PL2504005T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
PL13170128T PL2641596T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL13170128T PL2641596T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Country Status (24)

Country	Link
US (2)	US8772342B2 (pl)
EP (2)	EP2504005B1 (pl)
JP (4)	JP5833016B2 (pl)
KR (2)	KR101865677B1 (pl)
CN (2)	CN102647982B (pl)
AU (1)	AU2010323066B2 (pl)
BR (1)	BR112012012815B8 (pl)
CA (1)	CA2781451C (pl)
CY (2)	CY1116548T1 (pl)
DK (2)	DK2504005T3 (pl)
EA (1)	EA020849B1 (pl)
ES (2)	ES2681794T3 (pl)
HU (1)	HUE039731T2 (pl)
IL (2)	IL219914A (pl)
LT (1)	LT2641596T (pl)
MX (1)	MX2012006062A (pl)
NZ (1)	NZ600439A (pl)
PH (1)	PH12012501054A1 (pl)
PL (2)	PL2504005T3 (pl)
PT (2)	PT2641596T (pl)
SI (2)	SI2641596T1 (pl)
TR (1)	TR201810393T4 (pl)
WO (1)	WO2011064350A1 (pl)
ZA (1)	ZA201204658B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10722575B2 (en)	2009-11-26	2020-07-28	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
LT2641596T (lt) *	2009-11-26	2018-08-10	Genfit	1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui
US9221751B2 (en)	2009-11-26	2015-12-29	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
KR101633720B1 (ko)	2011-01-31	2016-06-27	카딜라 핼쓰캐어 리미티드	지방이상증의 치료
EP2948137B1 (en) *	2013-01-18	2018-11-14	Genfit	Methods of treatment of fibrosis and cancers
UA114360C2 (uk)	2013-04-22	2017-05-25	Каділа Хелткере Лімітед	Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
US20160107989A1 (en)	2013-05-30	2016-04-21	Cadila Healthcare Limited	A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh)	2013-07-05	2015-04-16	Cadila Healthcare Ltd	協同性組成物
IN2013MU02470A (pl)	2013-07-25	2015-06-26	Cadila Healthcare Ltd
IN2013MU02905A (pl)	2013-09-06	2015-07-03	Cadila Healthcare Ltd
EA036342B1 (ru)	2014-06-13	2020-10-29	Инвентива	Применение панагониста ppar, а именно 5-хлор-1-[(6-бензотиазолил)сульфонил]-1н-индол-2-бутановой кислоты, для лечения фибротических состояний
EA036404B1 (ru)	2015-02-06	2020-11-06	Интерсепт Фармасьютикалз, Инк.	Фармацевтические композиции для комбинированной терапии
ES2891347T3 (es) *	2015-09-14	2022-01-27	Genfit	Métodos para diagnosticar y evaluar la esteatohepatitis no alcohólica
US10385017B2 (en)	2015-10-14	2019-08-20	Cadila Healthcare Limited	Pyrrole compound, compositions and process for preparation thereof
WO2017143038A1 (en) *	2016-02-16	2017-08-24	Concert Pharmaceuticals, Inc.	Deuterated gft-505
US11331292B2 (en)	2016-03-31	2022-05-17	Genfit	Methods of treatment of cholestatic diseases
US12053445B2 (en)	2016-03-31	2024-08-06	Genfit	Methods of treatment of cholestatic diseases
SMT202500241T1 (it) *	2016-03-31	2025-07-22	Genfit	Elafibranor per uso nel trattamento di colangite biliare primitiva
FR3056908B1 (fr) *	2016-09-30	2019-04-19	Nashpharm	Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
FR3056909B1 (fr)	2016-09-30	2019-04-19	Nashpharm	Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
MX382765B (es)	2016-12-09	2025-03-13	Zydus Lifesciences Ltd	Tratamiento para la colangitis biliar primaria.
CN110312705B (zh) *	2017-01-22	2021-07-09	苏州科睿思制药有限公司	Gft-505的晶型及其制备方法和用途
CA3051977A1 (en) *	2017-02-24	2018-08-30	Genfit	Pharmaceutical compositions for combination therapy
JP7266531B2 (ja)	2017-04-18	2023-04-28	ジェンフィ	エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ
CN111148742B (zh)	2017-11-30	2021-11-16	四川科伦博泰生物医药股份有限公司	芳香族化合物及其药物组合物和用途
US12030840B2 (en)	2018-08-03	2024-07-09	Genfit	Elafibranor salts
SG11202103011YA (en) *	2018-10-11	2021-04-29	Basf As	Aromatic compounds and pharmaceutical uses thereof
RU2702003C1 (ru) *	2019-03-18	2019-10-03	Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России)	Антистеатозное средство
JP7631217B2 (ja) *	2019-04-10	2025-02-18	ジェンフィット	式（ｉ）の化合物及びｇｌｐ－１受容体アゴニストを含む組合せ療法
CN110143890B (zh) *	2019-06-12	2020-12-22	天津科技大学	一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN110143902B (zh) *	2019-06-12	2021-06-04	天津科技大学	含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
US12522564B2 (en)	2020-02-10	2026-01-13	Genfit	Polymorphs of elafibranor
CN115884765A (zh)	2020-08-26	2023-03-31	基恩菲特公司	用于治疗原发性胆汁性胆管炎的组合物和方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04202129A (ja)	1990-11-30	1992-07-22	Terumo Corp	肝障害治療薬
SK20396A3 (en) *	1993-08-19	1997-03-05	Warner Lambert Co	Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base
WO2001046110A2 (en)	1999-12-23	2001-06-28	The University Of Georgia Research Foundation, Inc.	Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
CA2413878A1 (en) *	2000-06-20	2001-12-27	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders
KR100567125B1 (ko)	2001-11-01	2006-03-31	주식회사 안지오랩	칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841900B1 (fr)	2002-07-08	2007-03-02	Genfit S A	Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2841784B1 (fr) *	2002-07-08	2007-03-02		Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2857361B1 (fr)	2003-07-08	2005-09-09	Genfit S A	PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
WO2005073184A1 (fr)	2004-01-08	2005-08-11	Genfit	Composes derives de 1,3-diphenylprop-2-en-1-one, preparation et utilisations
JP4689331B2 (ja)	2005-04-19	2011-05-25	三菱電機株式会社	撮像装置
FR2902789A1 (fr) *	2006-06-21	2007-12-28	Genfit Sa	Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de)	2006-12-22	2008-06-26	Joh. Barth & Sohn Gmbh & Co. Kg	Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
LT2641596T (lt) *	2009-11-26	2018-08-10	Genfit	1,3-difenilprop-2-en-1-ono darinių panaudojimas kepenų sutrikimų gydymui

2010
- 2010-11-26 LT LTEP13170128.6T patent/LT2641596T/lt unknown
- 2010-11-26 PH PH1/2012/501054A patent/PH12012501054A1/en unknown
- 2010-11-26 EA EA201290389A patent/EA020849B1/ru not_active IP Right Cessation
- 2010-11-26 CN CN201080053762.8A patent/CN102647982B/zh active Active
- 2010-11-26 NZ NZ600439A patent/NZ600439A/en unknown
- 2010-11-26 SI SI201031723T patent/SI2641596T1/sl unknown
- 2010-11-26 PL PL10787363T patent/PL2504005T3/pl unknown
- 2010-11-26 BR BR112012012815A patent/BR112012012815B8/pt active IP Right Grant
- 2010-11-26 EP EP10787363.0A patent/EP2504005B1/en active Active
- 2010-11-26 SI SI201030472T patent/SI2504005T1/sl unknown
- 2010-11-26 CA CA2781451A patent/CA2781451C/en active Active
- 2010-11-26 DK DK10787363.0T patent/DK2504005T3/da active
- 2010-11-26 KR KR1020127016566A patent/KR101865677B1/ko active Active
- 2010-11-26 EP EP13170128.6A patent/EP2641596B1/en active Active
- 2010-11-26 ES ES13170128.6T patent/ES2681794T3/es active Active
- 2010-11-26 KR KR1020187008005A patent/KR101962209B1/ko active Active
- 2010-11-26 AU AU2010323066A patent/AU2010323066B2/en active Active
- 2010-11-26 WO PCT/EP2010/068346 patent/WO2011064350A1/en not_active Ceased
- 2010-11-26 DK DK13170128.6T patent/DK2641596T3/en active
- 2010-11-26 JP JP2012540447A patent/JP5833016B2/ja active Active
- 2010-11-26 PT PT131701286T patent/PT2641596T/pt unknown
- 2010-11-26 CN CN201410458131.4A patent/CN104434891B/zh active Active
- 2010-11-26 ES ES10787363.0T patent/ES2441665T3/es active Active
- 2010-11-26 PL PL13170128T patent/PL2641596T3/pl unknown
- 2010-11-26 MX MX2012006062A patent/MX2012006062A/es active IP Right Grant
- 2010-11-26 PT PT107873630T patent/PT2504005E/pt unknown
- 2010-11-26 US US13/511,170 patent/US8772342B2/en active Active
- 2010-11-26 HU HUE13170128A patent/HUE039731T2/hu unknown
- 2010-11-26 TR TR2018/10393T patent/TR201810393T4/tr unknown
2012
- 2012-05-21 IL IL219914A patent/IL219914A/en active IP Right Grant
- 2012-06-22 ZA ZA2012/04658A patent/ZA201204658B/en unknown
2014
- 2014-01-07 CY CY20141100010T patent/CY1116548T1/el unknown
- 2014-05-28 US US14/288,482 patent/US8895619B2/en active Active
2015
- 2015-09-21 IL IL241791A patent/IL241791A0/en active IP Right Grant
- 2015-10-28 JP JP2015212306A patent/JP2016074670A/ja active Pending
2017
- 2017-12-14 JP JP2017239237A patent/JP6594400B2/ja active Active
2018
- 2018-07-20 CY CY20181100759T patent/CY1120444T1/el unknown
2019
- 2019-09-24 JP JP2019173268A patent/JP2020073468A/ja active Pending

Also Published As

Publication number	Publication date
US8772342B2 (en)	2014-07-08
US20140309165A1 (en)	2014-10-16
EP2641596A1 (en)	2013-09-25
CN104434891A (zh)	2015-03-25
JP2016074670A (ja)	2016-05-12
MX2012006062A (es)	2012-06-28
TR201810393T4 (tr)	2018-08-27
EP2504005B1 (en)	2013-11-06
EA201290389A1 (ru)	2013-01-30
BR112012012815B8 (pt)	2021-05-25
KR101865677B1 (ko)	2018-07-16
SI2641596T1 (sl)	2018-09-28
KR20120101472A (ko)	2012-09-13
HK1175716A1 (en)	2013-07-12
CY1120444T1 (el)	2019-07-10
ES2441665T3 (es)	2014-02-05
EP2504005A1 (en)	2012-10-03
AU2010323066A1 (en)	2012-06-07
EP2641596B1 (en)	2018-05-02
CY1116548T1 (el)	2017-03-15
CN102647982B (zh)	2014-10-15
PH12012501054A1 (en)	2014-09-05
JP5833016B2 (ja)	2015-12-16
EA020849B1 (ru)	2015-02-27
DK2504005T3 (da)	2014-01-13
CN102647982A (zh)	2012-08-22
US8895619B2 (en)	2014-11-25
ES2681794T3 (es)	2018-09-17
IL241791A0 (en)	2015-11-30
IL219914A0 (en)	2012-07-31
WO2011064350A1 (en)	2011-06-03
NZ600439A (en)	2014-06-27
KR101962209B1 (ko)	2019-03-26
US20120252725A1 (en)	2012-10-04
KR20180031825A (ko)	2018-03-28
BR112012012815A8 (pt)	2018-02-27
LT2641596T (lt)	2018-08-10
JP2013512228A (ja)	2013-04-11
JP2020073468A (ja)	2020-05-14
SI2504005T1 (sl)	2014-04-30
HUE039731T2 (hu)	2019-01-28
BR112012012815A2 (pt)	2017-12-12
PT2504005E (pt)	2014-01-10
ZA201204658B (en)	2013-05-29
IL219914A (en)	2015-10-29
JP6594400B2 (ja)	2019-10-23
BR112012012815B1 (pt)	2021-02-02
DK2641596T3 (en)	2018-08-06
EA201290389A8 (ru)	2014-05-30
PT2641596T (pt)	2018-07-31
AU2010323066B2 (en)	2014-12-11
CA2781451A1 (en)	2011-06-03
CN104434891B (zh)	2018-03-30
PL2641596T3 (pl)	2018-10-31
JP2018070642A (ja)	2018-05-10
CA2781451C (en)	2019-04-16

Publication	Publication Date	Title
PL2504005T3 (pl)	2014-03-31	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
LTC2137143I2 (lt)	2023-10-10	Pleuromutilino dariniai, skirti mikrobų sukeltų ligų gydymui
PL3354276T3 (pl)	2020-09-21	Kompozycje do leczenia zapalenia przewodu pokarmowego
SMAP200900085A (it)	2010-01-19	3-imidazolil-indoli per il trattamento di malattieproliferative
HUE061548T2 (hu)	2023-07-28	Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
DK3456707T3 (da)	2020-07-20	4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
PL2338519T3 (pl)	2016-06-30	Środek do leczenia zwłóknienia szpiku
BRPI0911577A8 (pt)	2018-03-06	derivados espiro-indol para o tratamento de doenças parasíticas.
ZA201001264B (en)	2011-07-27	1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
BRPI1009783A2 (pt)	2016-03-08	compostos para o tratamento de distúrbios metabólicos.
HUE040085T2 (hu)	2019-02-28	PDE7 inhibitorok alkalmazása mozgási rendellenességek kezelésére
IL209336B (en)	2018-07-31	Compositions for treating hyperproliferative diseases and uses thereof
DK2146991T3 (da)	2010-11-22	Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
PL2229369T3 (pl)	2017-01-31	Pochodne 6,7-dialkoksychinazoliny użyteczne do leczenia zaburzeń związanych z rakiem
BRPI1013245A2 (pt)	2016-04-05	"composto para o tratamento de distúrbios metabólicos"
BRPI0820440A2 (pt)	2015-05-26	Inibidores aldh-2 no tratamento de desordens psiquiátricas
SMT201600041B (it)	2016-02-25	Agenti terapeutici 713
BRPI0821026A2 (pt)	2015-06-16	Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
IL209417A0 (en)	2011-01-31	1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
SMT201300156B (it)	2014-03-07	Composti solfonammidici per il trattamento di disturbi respiratori
SI2278962T1 (sl)	2014-05-30	Postopki za zdravljenje dermatoloĹˇkih motenj
ES1075748Y (es)	2012-02-24	"flexo para duchas o similares"
BRPI0816713A2 (pt)	2016-11-08	derivados de 1-amino-alquilciclohexano para o tratamento de tinnitus coclear